ArticleMolecular neurobiology2025
Pachymic Acid Promotes ILC2 Migration to the Brain via Dynein Axonemal Heavy Chain 9 Upregulation.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pachymic Acid (PA), identified for its potential therapeutic efficacy in cerebral ischemic injury, has raised questions regarding its underlying molecular mechanisms. This investigation delineates the role of PA in modulating the migration of intestinal type 2 innate lymphoid cells (ILC2s) and its consequent impact on ameliorating brain ischemic injury. The Middle Cerebral Artery Occlusion/Reperfusion (MCAO/R) mouse model was established using C57BL/6 mice and treated with PA pre- and post-injury. Transcriptome sequencing was performed to assess potential genes regulated by PA. ILC2s were isolated for in vivo transfer experiments. Mice were euthanized at 6, 12, and 24 h after MCAO/R surgery to assess the relationship between ILC2s aggregation and the duration of MCAO/R injury. Pathological damage to brain and intestine tissue was assessed using histopathological, biochemical analysis and immunochemical techniques. PA significantly alleviated inflammation and neuronal apoptosis in the brain tissue after MCAO/R in mice. Notably, PA restored intestinal barrier function, reinforcing intestinal tight junctions and diminishing systemic lipopolysaccharide (LPS) levels. Upon Interleukin-33 (IL-33) activation, a surge in ILC2s was observed at 6 h post-MCAO/R, markedly reducing inflammation and apoptosis in the brain tissue. Intriguingly, ILC2s migrated from the intestine to the brain post-MCAO/R injury. Pre-treatment with PA expedited this migration, leading to an increased accumulation of ILC2s in the brain tissue. Transcriptomic analysis revealed that PA reversed 24% of the aberrantly expressed genes induced by MCAO/R. Moreover, overexpression of Dynein Axonemal Heavy Chain 9 (DNAH9) significantly attenuated both intestinal and cerebral damage in the MCAO/R model, whereas the protective effects of PA were reversed by DNAH9 knockdown. Collectively, these data underscore the pivotal role of ILC2s migration in brain injury repair, with PA mediating this migration through DNAH9 expression modulation. These findings provide robust support for the development of ischemic stroke therapeutics and the exploration of new treatment targets.
Indexed as
Identifiers
41335398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.